Taken together, these results suggest that while HMGB2 may play a role in the progression of grades 2 and 3 diffuse gliomas, in fully developed grade 4 diffuse astrocytomas, higher HMGB2 expression may be a biomarker of treatment response. This evidence concerns the gene HMGB2 and diffuse astrocytoma.